Amphotericin b liposome inj
Products billed under this code include Ambisome, Amphotericin B Liposome.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Ambisome, Amphotericin B Liposome.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Ambisome | Astellas Pharma US, Inc. | 00469-3051-30 | 5 | $89.255 |
| Amphotericin B Liposome | Heritage Pharmaceuticals Inc. | 23155-0594-31 | 5 | $89.255 |
| Amphotericin B Liposome | Eugia US LLC | 55150-0365-01 | 5 | $89.255 |
| Amphotericin B Liposome | Sun Pharmaceutical Industries, Inc. | 62756-0233-01 | 5 | $89.255 |
| Amphotericin B Liposome | Mylan Institutional LLC | 67457-0926-50 | 5 | $89.255 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $17.851 | −$1.994 | 10 MG | Amphotericin b liposome inj | v1, posted September 17, 2026 |
| 3Q26 | $19.845 | −$2.962 | 10 MG | Amphotericin b liposome inj | v1, posted September 15, 2026 |
| 2Q26 | $22.807 | +$2.086 | 10 MG | Amphotericin b liposome inj | v1, posted September 15, 2026 |
| 1Q26 | $20.721 | −$0.762 | 10 MG | Amphotericin b liposome inj | v1, posted September 15, 2026 |
| 4Q25 | $21.483 | −$1.133 | 10 MG | Amphotericin b liposome inj | v1, posted September 8, 2026 |
| 3Q25 | $22.616 | −$0.691 | 10 MG | Amphotericin b liposome inj | v1, posted March 10, 2026 |
| 2Q25 | $23.307 | −$0.668 | 10 MG | Amphotericin b liposome inj | v1, posted March 10, 2026 |
| 1Q25 | $23.975 | +$0.65 | 10 MG | Amphotericin b liposome inj | v1, posted December 19, 2025 |
| 4Q24 | $23.325 | +$1.694 | 10 MG | Amphotericin b liposome inj | v1, posted June 11, 2025 |
| 3Q24 | $21.631 | −$6.051 | 10 MG | Amphotericin b liposome inj | v1, posted June 11, 2025 |
| 2Q24 | $27.682 | +$1.024 | 10 MG | Amphotericin b liposome inj | v1, posted March 11, 2025 |
| 1Q24 | $26.658 | −$1.265 | 10 MG | Amphotericin b liposome inj | v1, posted December 19, 2024 |
| 4Q23 | $27.923 | +$0.052 | 10 MG | Amphotericin b liposome inj | v1, posted October 10, 2024 |
| 3Q23 | $27.871 | +$1.02 | 10 MG | Amphotericin b liposome inj | v1, posted June 5, 2024 |
| 2Q23 | $26.851 | +$2.331 | 10 MG | Amphotericin b liposome inj | v1, posted February 23, 2024 |
| 1Q23 | $24.52 | −$1.384 | 10 MG | Amphotericin b liposome inj | v1, posted December 6, 2023 |
| 4Q22 | $25.904 | −$0.459 | 10 MG | Amphotericin b liposome inj | v1, posted June 22, 2023 |
| 3Q22 | $26.363 | −$1.015 | 10 MG | Amphotericin b liposome inj | v1, posted June 9, 2023 |
| 2Q22 | $27.378 | −$2.089 | 10 MG | Amphotericin b liposome inj | v1, posted December 14, 2022 |
| 1Q22 | $29.467 | +$0.72 | 10 MG | Amphotericin b liposome inj | v1, posted June 8, 2022 |
| 4Q21 | $28.747 | +$0.413 | 10 MG | Amphotericin b liposome inj | v1, posted June 2, 2022 |
| 3Q21 | $28.334 | +$1.267 | 10 MG | Amphotericin b liposome inj | v1, posted June 2, 2022 |
| 2Q21 | $27.067 | −$0.172 | 10 MG | Amphotericin b liposome inj | v1, posted March 1, 2022 |
| 1Q21 | $27.239 | – | 10 MG | Amphotericin b liposome inj | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.